Drugs / Neoantigen specific TCR-T cell drug product
Neoantigen specific TCR-T cell drug product
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05194735 | Apr 2022 → Aug 2023 | adenosquamous lung carcinoma, cholangiocarcinoma, colorectal cancer, endometrial cancer +3 | Alaunos Therapeutics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen specific TCR-T cell drug product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05194735 ↗ |
| Modality | Cell therapy | “autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s)” NCT05194735 ↗ |